Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04440592 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis
A Phase 2 study of Diffuse Cutaneous Systemic Sclerosis, sponsored by Tanabe Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 20
- Study locations
NCT04440592 is a Phase 2 study of Diffuse Cutaneous Systemic Sclerosis that has completed, run by Tanabe Pharma America. The registered enrollment target is 76 participants, below the 92-participant average among 6 other Diffuse Cutaneous Systemic Sclerosis trials with a reported enrollment target (17% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT04440592, a Phase 2 study of Diffuse Cutaneous Systemic Sclerosis, has completed, sponsored by Tanabe Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the efficacy of MT-7117 treatment in subjects with diffuse cutaneous systemic sclerosis (dcSSc) using the American College of Rheumatology Composite Response Index in Diffuse Systemic Sclerosis (ACR CRISS) at Week 52
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MT-7117
Study Locations (20)
Other
- Universitair Ziekenhuis Gent - Ghent
- Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Liège
- Internistisches Zentrum des Universitaetsklinikums Erlangen - Erlangen
California
- Pacific Arthritis Care Center - Los Angeles
- The Board of Trustees of the Leland Stanford Junior University - Redwood City
Florida
- GNP Research - Hollywood
- Millennium Research - Ormond Beach
Arizona
- Arizona Arthritis - Glendale
Connecticut
- Yale School of Medicine - The Anlyan Center (TAC) for Medical Research & Education - New Haven
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2021-02-05 |
| Est. Completion | 2024-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04440592
The ClinicalTrials.gov registry entry for NCT04440592 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 92-participant average among 6 other Diffuse Cutaneous Systemic Sclerosis trials with a reported enrollment target (17% lower). The listed sponsor is Tanabe Pharma America, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diffuse Cutaneous Systemic Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04440592 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04440592 about?
NCT04440592 is a clinical study titled "Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis". To evaluate the efficacy of MT-7117 treatment in subjects with diffuse cutaneous systemic sclerosis (dcSSc) using the American College of Rheumatology Composite Response Index in Diffuse Systemic Sclerosis (ACR CRISS) at Week 52
What is the current status of trial NCT04440592?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2021-02-05. Estimated completion is 2024-02-14.
What conditions does trial NCT04440592 study?
This clinical trial studies the following conditions: Diffuse Cutaneous Systemic Sclerosis.
What interventions are being tested in trial NCT04440592?
The interventions under investigation include: Placebo (DRUG), MT-7117 (DRUG).
Who is sponsoring clinical trial NCT04440592?
This trial is sponsored by Tanabe Pharma America, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04440592 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Cutaneous Systemic Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
RECRUITING · Phase 2
-
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
COMPLETED · Phase 2
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
ACTIVE NOT RECRUITING · Phase 1
-
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.